Association between elevated CHA2DS2-VASC score and contrast-induced nephropathy among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

References

• Brown JR, Rezaee ME, Nichols EL, et al. Incidence and in-hospital mortality of acute kidney injury (AKI) and dialysis-requiring AKI (AKI-D) after cardiac catheterization in the national inpatient sample. J Am Heart Assoc. 2016;5(3):e002739.
   PubMed Web of Science ®Google Scholar
• Mohebi R, Karimi Galougahi K, Garcia JJ, et al. Long-Term clinical impact of contrast-associated acute kidney injury following PCI: an ADAPT-DES substudy. JACC Cardiovasc Interv. 2022;15(7):753–766.
   PubMed Web of Science ®Google Scholar
• Isaac T, Gilani S, Kleiman NS. When prevention is truly better than cure: contrast-associated acute kidney injury in percutaneous coronary intervention. Methodist Debakey Cardiovasc J. 2022;18(4):73–85.
   PubMedGoogle Scholar
• He H, Chen XR, Chen YQ, et al. Prevalence and predictors of contrast-induced nephropathy (CIN) in patients with ST-Segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI): a meta-analysis. J Interv Cardiol. 2019;2019:2750173.
   PubMed Web of Science ®Google Scholar
• Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–1399.
   PubMed Web of Science ®Google Scholar
• Gurm HS, Seth M, Kooiman J, et al. A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2013;61(22):2242–2248.
   PubMed Web of Science ®Google Scholar
• Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7(1):1–9.
   PubMed Web of Science ®Google Scholar
• Chandiramani R, Cao D, Nicolas J, et al. Contrast-induced acute kidney injury. Cardiovasc Interv Ther. 2020;35(3):209–217.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139–145.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Bagci A, Aksoy F. Predictive value of CHA2DS2-VASc and CHA2DS2-VASc-HS scores for developing contrast induced nephropathy in patients with ST-elevation myocardial infarction. Anatol J Cardiol. 2018;20:51.
   Google Scholar
• Baydar O, Kilic A. CHA2DS2-VASC score predicts risk of contrast-induced nephropathy in non-ST elevation myocardial infarction patients undergoing percutaneous coronary interventions. Kidney Dis. 2019;5(4):266–271.
   Web of Science ®Google Scholar
• Chaudhary AK, Pathak V, Kunal S, et al. CHA2DS2-VASc score as a novel predictor for contrast-induced nephropathy after percutaneous coronary intervention in acute coronary syndrome. Indian Heart J. 2019;71(4):303–308.
   PubMedGoogle Scholar
• Cicek G, Yıldırım E. CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention. Kardiol Pol. 2018;76(1):91–98.
   PubMed Web of Science ®Google Scholar
• Kumar R, Batra MK, Khowaja S, et al. CHA2DS2-VASc, a simple clinical score expanding its boundaries to predict contrast-induced acute kidney injury after primary percutaneous coronary interventions. Int J Nephrol Renovasc Dis. 2021;14:495–504.
   PubMed Web of Science ®Google Scholar
• Kurtul A, Yarlioglues M, Duran M. Predictive value of CHA2DS2-VASC score for contrast-induced nephropathy after percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2017;119(6):819–825.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao HW, Zhang XJ, et al. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience. BMC Cardiovasc Disord. 2019;19(1):74.
   PubMed Web of Science ®Google Scholar
• Michaud GF, Stevenson WG. Atrial fibrillation. N Engl J Med. 2021;384(4):353–361.
   PubMed Web of Science ®Google Scholar
• Rosenstock JL, Gilles E, Geller AB, et al. Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. Int Urol Nephrol. 2010;42(4):1049–1054.
   PubMed Web of Science ®Google Scholar
• Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94(3):300–305.
   PubMed Web of Science ®Google Scholar
• Pannu N, Wiebe N, Tonelli M, et al. Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295(23):2765–2779.
   PubMed Web of Science ®Google Scholar
• Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4):379–386.
   PubMed Web of Science ®Google Scholar
• Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347–1360.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States renal data system 2003 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(6 Suppl 5):A5. Suppl 5):A57
   PubMedGoogle Scholar
• Sommers SC, Relman AS, Smithwick RH. Histologic studies of kidney biopsy specimens from patients with hypertension. Am J Pathol. 1958;34(4):685–715.
   PubMed Web of Science ®Google Scholar
• Conen D, Buerkle G, Perruchoud AP, et al. Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention. Int J Cardiol. 2006;110(2):237–241.
   PubMed Web of Science ®Google Scholar
• Chen SL, Zhang J, Yei F, et al. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol. 2008;126(3):407–413.
   PubMed Web of Science ®Google Scholar
• Gussenhoven MJ, Ravensbergen J, van Bockel JH, et al. Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease. J Cardiovasc Surg. 1991;32(1):81–86.
   PubMed Web of Science ®Google Scholar
• Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13–19.
   PubMed Web of Science ®Google Scholar
• Abdel-Ghany M, Morsy G, Kishk YT. Predictors of contrast-induced nephropathy in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Egypt J Intern Med. 2021;33(1):6.
   Google Scholar
• Heyman SN, Rosenberger C, Rosen S, et al. Why is diabetes mellitus a risk factor for contrast-induced nephropathy? Biomed Res Int. 2013;2013:123589.
   PubMed Web of Science ®Google Scholar
• Zhang H, Fu H, Fu X, et al. Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention. BMC Nephrol. 2021;22(1):206.
   PubMed Web of Science ®Google Scholar
• Lucreziotti S, Centola M, Salerno-Uriarte D, et al. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction. Int J Cardiol. 2014;174(1):37–42.
   PubMed Web of Science ®Google Scholar
• Wi J, Ko YG, Kim JS, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011;97(21):1753–1757.
   PubMed Web of Science ®Google Scholar
• Senoo T, Motohiro M, Kamihata H, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2010;105(5):624–628.
   PubMed Web of Science ®Google Scholar
• Gill NK, Piccione EA, Vido DA, et al. Gender as a risk factor for contrast nephropathy: effects of hydration and N-acetylcysteine. Clin Cardiol. 2004;27(10):554–558.
   PubMed Web of Science ®Google Scholar
• Wang K, Li HL, Bei WJ, et al. Association of left ventricular ejection fraction with contrast-induced nephropathy and mortality following coronary angiography or intervention in patients with heart failure. Ther Clin Risk Manag. 2017;13:887–895.
   PubMed Web of Science ®Google Scholar
• Kaspar RW, Allen HD, Ray WC, et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet. 2009;2(6):544–551.
   PubMedGoogle Scholar
• Maioli M, Toso A, Leoncini M, et al. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. Circ Cardiovasc Interv. 2011;4(5):456–462.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tan N, Huo Y, et al. Hydration for prevention of kidney injury after primary coronary intervention for acute myocardial infarction: a randomised clinical trial. Heart. 2022;108(12):948–955.
   PubMed Web of Science ®Google Scholar